Illumina $ILMN Eyes 14x Growth Despite GRAIL Setback; Long-Term Target...
Illumina stands at a complex crossroads, balancing its genomic sequencing prowess with challenges from the GRAIL divestiture and growing competition. While tales of an "AI sleeper" with a 14-fold growth...